

Supplementary Information

Manuscript Title:

Trajectories of Patient-Reported Outcomes among Diverse Cancer Patients in Ambulatory Oncology Clinics.

Authors: Akina Natori, Blanca Silvia Noriega Esquivas, Vandana D. Sookdeo, Rui Gong, Jessica MacIntyre, Carmen Calfa, Tracy E. Crane, Matthew Schlumbrecht, Frank J. Penedo

Journal: Journal of Cancer Survivorship

Corresponding Author: Frank J. Penedo, PhD

Professor of Psychology and Medicine, Miller School of Medicine, University of Miami

Associate Director for Cancer Survivorship and Translational Behavioral Sciences

Director of Cancer Survivorship and Supportive Care, Sylvester Comprehensive Cancer Center

1120 NW 14th Street, Miami, FL 33136

Email: fpenedo@miami.edu

Table S1. Sample size for each timepoint by cancer type.

	T1-T3 N (%)^{&}	T4 N (%)^{\$}
Cancer Site		
Breast	401 (10%)	250 (62%)
GYN	227 (6%)	130 (57%)
GI	766 (20%)	501 (65%)
Head and Neck	412 (11%)	266 (65%)
Hematologic	991 (26%)	583 (59%)
Lung	334 (9%)	217 (65%)
MGS	678 (18%)	376 (56%)
Total	3,809 (100%)	2,323 (61%)

&: column percentages; \$: row percentages.

Table S2. Intervals between baseline and follow-up assessments.

Time since baseline (Months)	T2	T3	T4
Range	1 – 15.4	2.1 – 18.5	3.4 – 18.4
Mean	3.4	6.2	8.4

Table S3. Differences between Completers vs. Non-completers at Baseline.

	Completers (n=2,323)		Non-Completers (n=1,486)		p
	Mean or N	SD or %	Mean or N	SD or %	
Age	63.97	12.49	64.39	12.55	0.301
Female	1070	46.06	664	44.68	0.409
Partnered	1505	64.84	951	64.04	0.817
Insured	2288	98.58	1463	98.52	0.880
Race/Ethnicity					0.029
Non-Hispanic White	1016	45.77	606	42.71	
Non-Hispanic Black	183	8.24	122	8.60	
Non-Hispanic Other	69	3.11	28	1.97	
Hispanic	952	42.88	663	46.72	
Charlson Comorbidity Index	7.13	3.61	6.12	3.71	<.001
Cancer Site					<.001
Breast	250	10.76	151	10.16	
GYN	130	5.60	265	6.53	
GI	501	21.57	97	17.83	
Head and Neck	266	11.45	146	9.83	
Hematologic	583	25.10	408	27.46	
Lung	217	9.34	117	7.87	
MGS	376	16.19	302	20.32	
Years since diagnosis	3.33	3.21	3.67	3.49	0.003
Metastatic disease	560	24.13	251	16.90	<.001
Treatment Type					
Chemotherapy	717	30.87	312	21.00	<.001
Immunotherapy	144	6.20	52	3.50	<.001
Hormonal Therapy	198	8.52	83	5.59	<.001
Surgery	107	4.61	100	6.73	0.005
Radiation	54	2.32	25	1.68	0.175
Patient Reported Outcome					
Anxiety	51.68	9.38	50.52	9.83	<.001
Depression	46.44	9.30	45.88	9.22	0.084
Pain Interference	51.08	10.55	51.00	10.60	0.834
Fatigue	48.60	10.69	47.82	11.28	0.042
Physical Function	44.82	10.61	45.47	10.86	0.087
HRQOL	19.38	5.43	19.64	5.68	0.199

Completers: Patients who completed five assessments; non-completers: patients who completed three or four assessments. GI; gastrointestinal cancer, GYN; gynecological cancer, HRQOL; health-related quality of life, MGS: Male genital system cancer, SD; standard deviation.

Table S4. Predicted Patient-Reported Outcomes Scores at Each Time Point by Cancer Type

	Breast		GYN		GI		Head and Neck		Hematologic		Lung		MGS		Pairwise Comparison with Significant Difference
	Predicted Mean	SE	Predicted Mean	SE	Predicted Mean	SE	Predicted Mean	SE	Predicted Mean	SE	Predicted Mean	SE	Predicted Mean	SE	
PROMIS Anxiety															
T0	50.77	1.02	51.75	1.13	49.67	0.99	49.52	1.02	50.47	1.00	50.64	1.03	48.16	0.97	6,7,8,11,15,20,21
T1	50.38	1.00	51.20	1.10	49.30	0.98	48.88	1.00	49.80	0.99	50.13	1.02	47.59	0.96	6,8,11,15,20,21
T2	49.99	1.01	50.64	1.12	48.92	0.99	48.25	1.01	49.13	0.99	49.63	1.03	47.03	0.97	6,8,11,15,20,21
T3	49.73	1.03	50.26	1.16	48.67	1.01	47.82	1.03	48.68	1.00	49.30	1.06	46.88	0.98	6,8,11,15,20,21
PROMIS Depression															
T0	47.16	1.00	48.29	1.10	46.33	0.97	46.22	1.00	46.86	0.98	46.89	1.01	45.50	0.95	7,11,20
T1	46.89	0.99	48.03	1.08	46.36	0.96	46.04	0.98	46.73	0.97	47.06	0.99	45.48	0.94	8,11,20
T2	46.62	0.99	47.77	1.08	46.39	0.96	45.87	0.99	46.60	0.97	47.23	1.00	45.45	0.94	8,11,21
T3	46.44	1.01	47.59	1.12	46.41	0.98	45.75	1.00	46.51	0.98	47.34	1.01	45.44	0.96	8,11,21
PROMIS Pain Interference															
T0	53.05	1.07	55.37	1.19	52.25	1.04	53.15	1.06	54.00	1.04	52.73	1.08	51.78	1.01	7,10,11,13,20
T1	53.19	1.05	55.07	1.15	52.24	1.03	52.69	1.05	53.86	1.03	52.57	1.06	51.46	1.00	6,7,8,10,11,13,20
T2	53.33	1.06	54.77	1.16	52.22	1.03	52.24	1.05	53.72	1.03	52.41	1.06	51.14	1.00	6,7,8,10,11,16,20
T3	53.43	1.07	54.58	1.20	52.21	1.04	51.94	1.06	53.63	1.04	52.30	1.07	50.93	1.01	6,7,8,10,11,16,20
PROMIS Fatigue															
T0	49.42	1.17	51.57	1.29	49.23	1.14	48.67	1.17	51.36	1.14	48.94	1.18	47.19	1.11	6,7,8,10,11,13,15,16,19,20
T1	49.38	1.15	51.63	1.26	49.35	1.13	48.14	1.15	51.01	1.13	49.31	1.16	47.37	1.10	6,7,8,10,11,13,15,16,20,21
T2	49.33	1.16	51.68	1.27	49.47	1.14	47.61	1.15	50.66	1.14	49.68	1.16	47.55	1.11	1,7,8,11,12,15,16,17,20,21
T3	49.30	1.18	51.72	1.29	49.55	1.15	47.26	1.17	50.43	1.14	49.93	1.18	47.67	1.11	1,8,11,12,15,16,17,20,21
PROMIS Physical Function															
T0	42.42	1.08	39.74	1.20	42.48	1.05	43.33	1.08	40.94	1.06	42.74	1.09	45.34	1.03	1,6,7,8,10,11,13,15,16,18,20,21
T1	42.34	1.06	39.70	1.16	42.39	1.04	43.79	1.06	41.21	1.05	42.40	1.07	45.41	1.02	1,6,7,8,10,11,15,16,18,20,21
T2	42.27	1.06	39.65	1.17	42.30	1.04	44.25	1.06	41.48	1.05	42.05	1.07	45.48	1.02	1,3,6,7,8,10,11,12,15,16,17,20,21
T3	42.21	1.08	39.62	1.19	42.25	1.05	44.55	1.07	41.66	1.05	41.82	1.09	45.53	1.02	1,3,6,7,8,9,11,12,15,16,17,20,21
FACT-G7 HRQOL															
T0	19.16	0.60	17.93	0.66	18.96	0.58	18.73	0.59	18.27	0.58	18.92	0.60	19.86	0.57	11,15,18,20
T1	19.15	0.59	17.94	0.64	18.85	0.57	19.02	0.59	18.36	0.58	18.87	0.59	19.89	0.56	1,11,15,18, 20,21
T2	19.15	0.59	17.96	0.64	18.75	0.57	19.31	0.59	18.45	0.58	18.82	0.59	19.92	0.56	1,8,11,15,16, 20,21
T3	19.15	0.59	17.98	0.65	18.68	0.58	19.50	0.59	18.51	0.58	18.79	0.60	19.94	0.56	1,8,11,15,16,20,21

GI; gastrointestinal cancer, GYN; gynecological cancer, HRQOL; health-related quality of life, MGS: Male genital system cancer, SE; standard error.

Statistically significant *p* values (Bonferroni-adjusted *p*<.0083): 1=Breast vs. GYN, 2=Breast vs. GI, 3=Breast vs. Head and neck, 4=Breast vs.

Hematologic, 5=Breast vs. Lung, 6=Breast vs. MGS, 7=GYN vs. GI, 8=GYN vs. Head and neck, 9=GYN vs. Hematologic, 10=GYN vs. Lung, 11=GYN

vs. MGS, 12=GI vs. Head and neck, 13=GI vs. Hematologic, 14=GI vs. Lung, 15=GI vs. MGS, 16=Head and neck vs. Hematologic, 17=Head and neck

vs. Lung, 18=Head and neck vs. MGS, 19=Hematologic malignancy vs. Lung, 20=Hematologic malignancy vs. MGS, 21=Lung vs. MGS